ClinTec ceo receives Honorary Doctorate
For her contribution to life sciences industry
This honorary doctorate was awarded in recognition of Dr Buttar’s contribution to the life sciences Industry over 20 years and for the foundation and development of ClinTec International.
Professor Seamus McDaid, principal and vice chancellor of the University of the West of Scotland, said: ‘We are delighted to award Dr Buttar with an Honorary Doctorate. As chief executive of ClinTec International, she is one of the country’s most important business leaders, making a hugely important contribution to the Scottish economy.’
At the graduation ceremony, which took place in Paisley, Dr Buttar said: ‘The University has created an exceptional pool of local and international graduates and I am honoured to come back here after 20 years and accept this degree. These graduates here today have successfully completed one chapter of their lives and as they open the next one their learning should never stop.
‘In the current challenging times, graduates should seek local as well as global opportunities, look to do something they feel passionate about, be even more determined than ever before to succeed and then further success will be in their hands. The University and its excellent staff have prepared them well for the challenges that lie ahead.
‘I feel honoured and privileged to join the Court and Senate today in recognising and celebrating in some of Scotland’s academic achievements.’
Dr Buttar has also been named as the Ernst & Young Entrepreneur of the Year for Scotland and the Institute of Directors’ Regional Director of the Year for the West of Scotland.
You may also like
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing
BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany
The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
Finance
Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings
The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected performance from its oral Wegovy pill
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.